Foghorn Therapeutics (FHTX) EBIT (2019 - 2026)

Foghorn Therapeutics' EBIT history runs 8 years deep, the most recent figure standing at -$21.6 million for Q1 2026.

• In Q1 2026, EBIT rose 5.85% year-over-year to -$21.6 million; the TTM figure through Mar 2026 stood at -$85.0 million (up 12.68% YoY), while the FY2025 annual figure was -$86.4 million, up 15.87% from the prior year.
• EBIT was -$21.6 million for Q1 2026 at Foghorn Therapeutics, up from -$23.9 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$17.1 million in Q3 2023 to a low of -$33.3 million in Q1 2023.
• Historically, EBIT has averaged -$25.6 million across 5 years, with a median of -$25.5 million in 2023.
• The sharpest annual moves came in 2023 and 2024: EBIT surged 39.56% in 2023, then sank 39.64% in 2024.
• A 5-year view of EBIT shows it stood at -$31.9 million in 2022, then rose by 20.16% to -$25.5 million in 2023, then rose by 5.71% to -$24.0 million in 2024, then grew by 0.53% to -$23.9 million in 2025, then rose by 9.65% to -$21.6 million in 2026.
• The last three EBIT figures came in at -$21.6 million (Q1 2026), -$23.9 million (Q4 2025), and -$18.5 million (Q3 2025), per Business Quant data.